IER5L Facilitates the Progression of Hormone Receptor-Positive Breast Cancer by Inhibiting HSF1 Phosphorylation in Response to Bevacizumab.
Medicine
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.